Rain Enhancement Technologies Holdco, Inc. · NASDAQ:RAIN
Rain Enhancement Technologies Holdco — Rain Therapeutics — Investor Presentation (November 2022)
24 slides from Rain Enhancement Technologies Holdco's investor presentation, Nov 4, 2022
Slide 1: Rain Therapeutics Management Presentation Nov. 2022
Exhibit 99.1 Rain Therapeutics M a n a g e m e n t P r e s e n t a t i o n N o v. 2022
Slide 2: Forward Looking Statements
R A I N T H E R A P E U T I C S Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements
Slide 3: Rain Therapeutics Overview
R A I N T H E R A P E U T I C S Rain Therapeutics Overview Milademetan (RAIN-32), an oral MDM2 inhibitor, represents a “pipeline in a program” opportunity CASH PRECISION ONCOLOGY PRECISION ONCOLOGY RUNWAY STRATEGY STRATEGY Precision oncology, small molecule ON-GOING PLANNED 3Q 2022 ending cash of ~$
Slide 4: Rain's Corporate Leadership
R A I N T H E R A P E U T I C S Rain’s Corporate Leadership Avanish Vellanki, MBS, MBA Robert Doebele, MD, PhD Richard Bryce, MBChB Nelson Cabatuan, CPA Cofounder, Chairman and Cofounder, President & Executive VP & Senior VP, Chief Executive Officer Chief Scientific Officer Chief Medical Officer Fin
Slide 5: Milademetan Value Proposition
R A I N T H E R A P E U T I C S Milademetan Value Proposition Key RAIN Perspectives on a clinical stage, oral, small molecule inhibitor of the MDM2-p53 complex Dosing Schedule Supports Efficacy Targeted Clinical Strategy to Maximize Opportunities • Identified intermittent • Targeting large schedule
Slide 6: Milademetan Strategy: Identifying MDM2 Dependence
R A I N T H E R A P E U T I C S Milademetan Strategy: Identifying MDM2 Dependence The market opportunity in p53 WT cancers is large, with the initial strategy for milademetan focused on cancers exhibiting MDM2-dependence p53 WT Cancer Market Opportunity Clinical Indications MDM2-Dependent Cancers p5
Slide 7: MDM2-p53 Axis & Milademetan MoA
R A I N T H E R A P E U T I C S MDM2-p53 Axis & Milademetan MoA Wildtype p53 responds to normal cellular injury to protect against cancer via induction of cellular apoptosis or senescence • Mutated p53 incapable of target gene binding and function Dysregulated MDM2 can facilitate or support oncogeni
Slide 8: Rain Therapeutics Pipeline
R A I N T H E R A P E U T I C S Rain Therapeutics Pipeline Rain’s pipeline encompasses a late clinical stage program in MDM2-dependent cancers, and an early research program for a novel target in DNA repair Milademetan (RAIN-32) 2022 ELIGIBLE INDICATION MANTRA PRECLINICAL PHASE 1 PHASE 2 PHASE 3 PAR
Slide 9: Summary: Ongoing Clinical Trials for Milademetan
R A I N T H E R A P E U T I C S Summary: Ongoing Clinical Trials for Milademetan T R I A L S C H E M A S E N D P O I N T S & P O P U L A T I O N • Primary / Secondary Endpoints: PFS, OS, DCR, ORR, DoR Milademetan • Unresectable / metastatic DD LPS ± WD component 260 mg, qd, 3/14 • Progression follow
Slide 10: Milademetan (Liposarcoma)
Milademetan ( L i p o s a r c o m a )
Slide 11: Liposarcoma Overview
R A I N T H E R A P E U T I C S Liposarcoma Overview T O T A L A D D R E S S A B L E M A R K E T 2 1 Liposarcomas 20% of all sarcomas Liposarcoma US annual incidence ~3,500 WD/DD is 65% of LPS WD/DD LPS incidence p53 WT & MDM2 amplified in ~2,300 3-6 nearly 100% of WDLS/DDLS cases TAM in WD/DD LPS ~
Slide 12: Milademetan Phase 1 (U101) Trial Select Treatment Emergent Adverse Events
R A I N T H E R A P E U T I C S Milademetan Phase 1 (U101) Trial Select Treatment Emergent Adverse Events Schedule A, B, and C Cohorts (n=78) Schedule D All doses (n=29) Schedule D 260mg (n=20) Organ Class n (%) All Grades Grade ≥ 3 Dosing Schedule All Grades Grade ≥ 3 All Grades Grade ≥ 3 for 4 Coh
Slide 13: Milademetan Phase 1 (U101) Trial Observed Progression Free Survival in LPS Patients
R A I N T H E R A P E U T I C S Milademetan Phase 1 (U101) Trial Observed Progression Free Survival in LPS Patients P R O G R E S S I O N - F R E E S U R V I V A L : L P S P AT I E N T S O N LY Phase 1 results revealed Schedule A/B Schedule C/D Schedule D, 260mg (n=30) (n=23) (n=16) PFS data for n=5
Slide 14: Milademetan Phase 2 MANTRA-2 (MDM2 Amp Basket)
Milademetan P h a s e 2 M A N T R A -2 ( M D M 2 A m p B a s k e t )
Slide 15: MANTRA-2 Study & Status
R A I N T H E R A P E U T I C S MANTRA-2 Study & Status MANTRA-2 trial is evaluating milademetan monotherapy in patients with MDM2 gene amplified and p53 wild type advanced solid tumors Overview Patient Demographics All Subjects N = 15* • Targeting n=65 pts Age, years • 10 active centers in US Media
Slide 16: Interim MANTRA-2 Analysis: Patient Outcomes
R A I N T H E R A P E U T I C S Interim MANTRA-2 Analysis: Patient Outcomes Two (2) Partial Responses and two (2) near-PRs observed of 10 evaluable patients Patient Tumor Diameter Change Adrenal ACC UPS Gastric Bladder Breast Biliary NSCLC Pancreatic CTNNB1 MYB-NFIB None CDH1 RB1 PIK3CA IDH2 EGFR de
Slide 17: Interim MANTRA-2 Analysis: Duration on Therapy
R A I N T H E R A P E U T I C S Interim MANTRA-2 Analysis: Duration on Therapy Two (2) Partial Responses and two (2) near-PRs observed of 10 evaluable patients Patient Treatment Duration 3202-1010-003 Bilia 003 ry 3202-1010-0 UPS 004 04 1 009 3202-1003-009 ACC 005 3202-1006-005 Bladder 011 A total o
Slide 18: TEAE by Preferred Term: Regardless of Attribution
R A I N T H E R A P E U T I C S TEAE by Preferred Term: Regardless of Attribution (Safety Population) Preliminary AE data in-line with prior Phase 1 study of milademetan Safety Population Safety Population N=15 N=15 Any Grade Grade 3 or higher Any Grade Grade 3 or higher Subjects with any hematologi
Slide 19: Milademetan Phase 1/2 MANTRA-4 (CDKN2A Loss/WT p53 Basket)
Milademetan P h a s e 1 / 2 M A N T R A -4 ( C D K N 2 A L o s s / W T p 5 3 B a s k e t )
Slide 20: MANTRA-4: IO Combo in CDKN2A Loss, p53 WT Adv Solid Tumors
R A I N T H E R A P E U T I C S MANTRA-4: IO Combo in CDKN2A Loss, p53 WT Adv Solid Tumors 1 In the US, there are 45,000 patients annually with advanced cancers exhibiting p53 WT and CDKN2A loss 2 Mechanism: CDKN2A Loss Increases MDM2 Activity Milademetan Antiproliferative Potency 10,000 Exon 1ß CDK
Slide 21: MANTRA-4: Milademetan + Atezolizumab (Phase 1/2)
R A I N T H E R A P E U T I C S MANTRA-4: Milademetan + Atezolizumab (Phase 1/2) Key Objectives and Rain and Roche will evaluate the safety of MDM2 + PD-L1 inhibition in patients with CDKN2A Eligibility: loss, p53 wildtype adv solid tumors prior to commencing Phase 2 studies in MDM2- dependent popul
Slide 22: Key Upcoming Milestones
R A I N T H E R A P E U T I C S Key Upcoming Milestones Rain anticipates multiple near-term developmental milestones for milademetan Milademetan (RAIN-32) MDM2 inhibitor INDICATION 4Q 2022 1Q 2023 2Q 2023 WD/DD MANTRA Phase 3: Topline Results LPS MDM2-amplified MANTRA-2 Phase 2 Basket: Interim data
Slide 23: Appendix
Appendix
Slide 24: Rain's Corporate Governance
R A I N T H E R A P E U T I C S Rain’s Corporate Governance Board of Directors Scientific Advisory Board Avanish Vellanki, MBA Robert Doebele, MD, PhD Chairman & CEO, Rain Therapeutics President & CSO, Rain Therapeutics Aaron Davis, MBA Trever Bivona, MD, PhD CEO, Boxer Capital Professor in Residenc
Rain Therapeutics — Investor Presentation (November 2022) on 6ix